MAP2K7 and neoplasm: Indeed, the addition of anti-PD-L1 therapy to CDK4/6 and MEK inhibitors greatly increased the survival of mice bearing de novo MPNSTs, prolonged tumor regression, and cured ~10% of treated animals.